CAR T-cell therapy for children: Meeting patient and family needs

Chimeric antigen receptor T-cell therapy is a promising immunotherapy for children with refractory or relapsed acute lymphoblastic leukemia who otherwise have limited treatment options.

For many of these patients — especially those who have experienced multiple relapses — and their families, this has been a long, complicated journey. Many have experienced years of remissions and relapses and, as a result, often come to CAR T-cell therapy medically well-educated.